ICH GOOD CLINICAL PRACTICE (GCP) FOR CERTIFIED CLINICAL RESEARCH COORDINATOR (CCRC) PRACTICE EXAM (SAMPLE)

STUDY GUIDE

SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://ichgcpforccrc.examzify.com

Table of Contents

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. Which description best matches an Impartial Witness in clinical trials?

A. An independent body constituted of medical professionals and non-medical members, whose responsibility is to ensure the protection of rights, safety and well-being of human subjects involved in a trial and to provide public assurance by reviewing and approving/providing favorable opinion on, the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to be used in obtaining and documenting informed consent of the trial subjects.

B. A sponsor-appointed data manager

C. A member of the regulatory authority

D. An independent ethics committee that approves the protocol

2. To document that compensation to subjects for trial-related injury will be available, which locations are listed for documentation?

A. Investigator/Institution

B. Sponsor

C. Both Investigator/Institution and Sponsor

D. Regulatory Authorities

3. Before initiating the clinical trial(s), what should the sponsor submit to the appropriate authority(ies)?

A. Required application(s) for review, acceptance, and/or permission to begin the trial, dated and identifiable

B. A general verbal notice to regulatory authorities

C. The final results after completion

D. The subject consent forms

4. The sponsor's system for the disposition of unused IP should ensure what?

A. Proper disposal or alternative disposition in compliance with regulatory requirements

B. Disposal without documentation

C. Disposal only with sponsor consent

D. No disposal is needed

5. During the trial, what should the investigator provide to the IRB/IEC?

A. All documents subject to review.

B. Only the initial protocol.

C. Only adverse event reports.

D. Only consent forms updated during the trial.

6. How often should investigators check that each subject is following the instructions for using the investigational product?

A. At intervals appropriate for the trial.

B. Daily.

C. Weekly only.

D. Never.

7. The sponsor should utilize qualified individuals throughout all stages to do what?

A. Only for Final Report Drafting

B. From Designing the Protocol and CRFs to Analyzing and Preparing Interim and Final Reports

C. Only for Protocol Approval by Ethics Committee

D. Only for Statistical Analysis

8. What must be provided to the IRB/IEC to obtain its favorable opinion?

A. The current copy of protocol, informed consent form, and any other written information to be provided to subjects

B. The sponsor's marketing plan

C. A list of investigators' educational certificates

D. The trial's annual budget

9. In superiority trials, which approach most convincingly demonstrates efficacy?

A. Trials to Show Superiority are determined by comparing to historical controls

B. Demonstrating superiority to placebo in a placebo-controlled trial

C. Equivalence with non-inferiority objectives

D. Dose-response relationship studies in animals

10. In trials where enrollment can occur only with the consent of the subject's legally acceptable representative, if the subject is capable, what should occur regarding consent?

A. The subject should sign and personally date the written informed consent.

B. The legally acceptable representative's consent should be the sole basis for enrollment.

C. The subject's assent is sufficient for enrollment.

D. The investigator may proceed without any consent.

Answers

1. A
2. C
3. A
4. A
5. A
6. A
7. B
8. A
9. B
10. A

Explanations

1. Which description best matches an Impartial Witness in clinical trials?

A. An independent body constituted of medical professionals and non-medical members, whose responsibility is to ensure the protection of rights, safety and well-being of human subjects involved in a trial and to provide public assurance by reviewing and approving/providing favorable opinion on, the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to be used in obtaining and documenting informed consent of the trial subjects.

B. A sponsor-appointed data manager

C. A member of the regulatory authority

D. An independent ethics committee that approves the protocol

An impartial witness is an independent observer whose role is to ensure that informed consent is obtained freely and properly documented, especially when a subject cannot read or write. The description that best matches this is an independent ethics committee (IEC/IRB) composed of medical professionals and non-medical members, whose job is to protect the rights, safety, and well-being of participants and to provide public assurance by reviewing and approving the trial protocol, the investigator's qualifications, facilities, and the methods used to obtain and document informed consent. This framing emphasizes independence and protective oversight—the core idea behind the impartial witness. The other options describe roles that are not independent witnesses in the consent process (sponsor data manager, regulatory authority member) or are phrased more narrowly about protocol approval without the witnessing aspect.

2. To document that compensation to subjects for trial-related injury will be available, which locations are listed for documentation?

A. Investigator/Institution

B. Sponsor

C. Both Investigator/Institution and Sponsor

D. Regulatory Authorities

In GCP, the plan for compensating trial-related injuries must be documented in two places: at the Investigator/Institution and with the Sponsor. This dual documentation ensures the participant is informed about compensation before enrolling, and that both the site and the sponsor have verifiable records of the commitment. The informed consent form should state that compensation is available, and the sponsor should keep evidence of the coverage or insurance. Having documentation in both locations provides clear accountability and a ready path for claims; relying on a single location could create gaps in how compensation is accessed or verified.

3. Before initiating the clinical trial(s), what should the sponsor submit to the appropriate authority(ies)?

A. Required application(s) for review, acceptance, and/or permission to begin the trial, dated and identifiable

B. A general verbal notice to regulatory authorities

C. The final results after completion

D. The subject consent forms

Regulatory authorization must be obtained before starting a trial. The sponsor submits the required written applications for review, acceptance, and permission to begin the study, and these submissions must be dated and identifiable so authorities can track and approve the trial. Verbal notices aren't sufficient, final results aren't available until after completion, and while consent forms are essential documents, they aren't the formal submission used to grant permission to initiate the trial.

4. The sponsor's system for the disposition of unused IP should ensure what?

A. Proper disposal or alternative disposition in compliance with regulatory requirements

B. Disposal without documentation

C. Disposal only with sponsor consent

D. No disposal is needed

The key idea is ensuring that unused Investigational Product (IP) is handled in a controlled, auditable way that meets regulatory requirements. In a sponsor's IP disposition system, every unused item must be accounted for and disposed of or redirected in a manner that is legally compliant and traceable. This means there's a documented plan for what to do with the IP (return to sponsor, destruction, or another approved disposition), and the method chosen must conform to applicable laws and guidelines. The system records essential details—dates, quantities, lot numbers, reasons for disposal, the chosen disposition method, and who authorized and witnessed the action—and keeps clear records for audits or inspections. This ensures there's no unaccounted IP and that patient safety, data integrity, and regulatory compliance are maintained. Disposing without documentation or requiring consent as the sole condition would leave the IP untraceable and noncompliant, and doing nothing with IP isn't appropriate once it's unused.

5. During the trial, what should the investigator provide to the IRB/IEC?

A. All documents subject to review.

B. Only the initial protocol.

C. Only adverse event reports.

D. Only consent forms updated during the trial.

IRB/IEC oversight relies on the investigator keeping the board informed with every document that could affect participant protection or how the study is conducted. Throughout a trial, new information frequently emerges—protocol amendments, updated consent forms, serious adverse events, annual progress reports, and any other data that could change risk/benefit or how participants understand what they're agreeing to. The IRB/IEC reviews these items to decide whether ongoing approval is appropriate and whether informed consent remains valid. Therefore, the investigator should provide all documents subject to review, not just a subset. Offering only the initial protocol or only one type of document would leave the board without the full context needed to protect subjects and ensure regulatory compliance.

6. How often should investigators check that each subject is following the instructions for using the investigational product?

A. At intervals appropriate for the trial.

B. Daily.

C. Weekly only.

D. Never.

Ensuring that subjects follow the investigational product's instructions is an ongoing responsibility of the investigator, tied to both subject safety and data integrity. The frequency of checking adherence isn't a one-size-fits-all rule; it should be determined by the trial's protocol and monitoring plan, taking into account how complex the dosing is, how often the product is used, its safety profile, and how often subjects come in for visits. Checking adherence at intervals appropriate for the trial allows timely detection of noncompliance, enables retraining or clarifications as needed, and ensures that the exposure data and safety assessments are accurate. Fixed daily or weekly checks aren't universally required and can be impractical, while never monitoring would jeopardize participant protection and data quality.

7. The sponsor should utilize qualified individuals throughout all stages to do what?

A. Only for Final Report Drafting

B. From Designing the Protocol and CRFs to Analyzing and Preparing Interim and Final Reports

C. Only for Protocol Approval by Ethics Committee

D. Only for Statistical Analysis

In GCP, sponsors must involve qualified individuals throughout all stages of a trial to ensure quality, integrity, and regulatory compliance. This means having experts engaged from the design of the protocol and the case report forms all the way through data analysis, interim analyses, and the preparation of final reports and regulatory submissions. Each phase relies on appropriate expertise to ensure the protocol is sound, data are collected correctly, analyses are valid, and results are reported accurately. Focusing only on one aspect—such as final report drafting, protocol ethics approval, or statistical analysis—misses essential oversight at other stages and can compromise trial quality and participant safety. The broad involvement across design, execution, analysis, and reporting best captures how a sponsor should manage expertise throughout the entire study.

8. What must be provided to the IRB/IEC to obtain its favorable opinion?

A. The current copy of protocol, informed consent form, and any other written information to be provided to subjects

B. The sponsor's marketing plan

C. A list of investigators' educational certificates

D. The trial's annual budget

IRBs review the study plan and the information that will be given to participants to ensure that risks are reasonable and that participants can make an informed choice. To obtain a favorable opinion, investigators must provide the current protocol, the informed consent form, and any other written information that will be presented to subjects. This allows the IRB to assess the study design, safety protections, and how information about risks, benefits, procedures, and rights will be communicated to participants. The sponsor's marketing plan, investigators' educational certificates, and the trial budget are not the materials the IRB uses to grant initial approval. They may be relevant for other reasons, but they're not the basis for the favorable opinion focused on participant protection and informed consent.

9. In superiority trials, which approach most convincingly demonstrates efficacy?

A. Trials to Show Superiority are determined by comparing to historical controls

B. Demonstrating superiority to placebo in a placebo-controlled trial

C. Equivalence with non-inferiority objectives

D. Dose-response relationship studies in animals

Demonstrating efficacy is strongest when the experimental treatment is shown to outperform a placebo in a randomized, placebo-controlled trial. This design directly isolates the treatment effect from placebo responses and other biases, providing clear evidence that the intervention yields a real benefit beyond no active treatment. Historical controls are unreliable because patient populations and care practices change over time, which can bias comparisons. Equivalence or non-inferiority frameworks aim to show the new treatment is not worse than an active comparator within a margin, not to prove it works better. Animal dose–response studies are preclinical and do not establish efficacy in humans.

10. In trials where enrollment can occur only with the consent of the subject's legally acceptable representative, if the subject is capable, what should occur regarding consent?

A. The subject should sign and personally date the written informed consent.

B. The legally acceptable representative's consent should be the sole basis for enrollment.

C. The subject's assent is sufficient for enrollment.

D. The investigator may proceed without any consent.

Respect for the subject's autonomy means that when a person is capable of giving consent, they must provide their own informed consent. Even in trials where enrollment can occur only with the consent of a legally acceptable representative, if the subject is capable, the subject should sign and personally date the written informed consent. The legally acceptable representative cannot substitute their consent for the capable subject's consent in this situation. Assent is not the same as consent for an adult, and proceeding without any consent would violate GCP and ethical principles. This approach protects the subject's rights and maintains proper informed consent documentation.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://ichgcpforccrc.examzify.com

We wish you the very best on your exam journey. You've got this!